Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 188 entries
Sorted by: Best Match Show Resources per page
Medicinal species with gastroprotective activity found in the Brazilian Cerrado.

Fundamental & clinical pharmacology

Martins JL, Rodrigues OR, de Sousa FB, Fajemiroye JO, Galdino PM, Florentino IF, Costa EA.
PMID: 25753027
Fundam Clin Pharmacol. 2015 Jun;29(3):238-51. doi: 10.1111/fcp.12113. Epub 2015 Mar 31.

Peptic and/or duodenal ulcers are characterized by diverse acute and chronic ulcerative lesions that commonly arise in any portion of the gastric mucosa that is exposed to the aggressive action of gastric acid. The pathophysiology of peptic ulcers has...

Cite
Martins JL, Rodrigues OR, de Sousa FB, et al. Medicinal species with gastroprotective activity found in the Brazilian Cerrado. Fundam Clin Pharmacol. 2015;29(3):238-51doi: 10.1111/fcp.12113.
Martins, J. L., Rodrigues, O. R., de Sousa, F. B., Fajemiroye, J. O., Galdino, P. M., Florentino, I. F., & Costa, E. A. (2015). Medicinal species with gastroprotective activity found in the Brazilian Cerrado. Fundamental & clinical pharmacology, 29(3), 238-51. https://doi.org/10.1111/fcp.12113
Martins, José L R, et al. "Medicinal species with gastroprotective activity found in the Brazilian Cerrado." Fundamental & clinical pharmacology vol. 29,3 (2015): 238-51. doi: https://doi.org/10.1111/fcp.12113
Martins JL, Rodrigues OR, de Sousa FB, Fajemiroye JO, Galdino PM, Florentino IF, Costa EA. Medicinal species with gastroprotective activity found in the Brazilian Cerrado. Fundam Clin Pharmacol. 2015 Jun;29(3):238-51. doi: 10.1111/fcp.12113. Epub 2015 Mar 31. PMID: 25753027.
Copy Download .nbib Format: NLM
Some issues with composite endpoints in clinical trials.

Fundamental & clinical pharmacology

Chi GY.
PMID: 16313272
Fundam Clin Pharmacol. 2005 Dec;19(6):609-19. doi: 10.1111/j.1472-8206.2005.00370.x.

This article discusses some important issues that may arise in the current usage of composite endpoints as primary endpoints for demonstrating the efficacy of new drugs in clinical trials. The discussion focuses on time-to-event composite endpoints. Issues discussed include...

Cite
Chi GY. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol. 2005;19(6):609-19doi: 10.1111/j.1472-8206.2005.00370.x.
Chi, G. Y. (2005). Some issues with composite endpoints in clinical trials. Fundamental & clinical pharmacology, 19(6), 609-19. https://doi.org/10.1111/j.1472-8206.2005.00370.x
Chi, George Y H. "Some issues with composite endpoints in clinical trials." Fundamental & clinical pharmacology vol. 19,6 (2005): 609-19. doi: https://doi.org/10.1111/j.1472-8206.2005.00370.x
Chi GY. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol. 2005 Dec;19(6):609-19. doi: 10.1111/j.1472-8206.2005.00370.x. PMID: 16313272.
Copy Download .nbib Format: NLM
Management of hypertension in adults: the 2013 French Society of Hypertension guidelines.

Fundamental & clinical pharmacology

Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X.
PMID: 23952903
Fundam Clin Pharmacol. 2014 Feb;28(1):1-9. doi: 10.1111/fcp.12044. Epub 2013 Aug 19.

To improve the management of hypertension in the French population, the French Society of Hypertension has decided to issue a new set of guidelines that include the following practical characteristics: usefulness for clinical practice, short, easy-to-read format, comprehensive writing...

Cite
Blacher J, Halimi JM, Hanon O, et al. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol. 2013;28(1):1-9doi: 10.1111/fcp.12044.
Blacher, J., Halimi, J. M., Hanon, O., Mourad, J. J., Pathak, A., Schnebert, B., Girerd, X. (2014). Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundamental & clinical pharmacology, 28(1), 1-9. https://doi.org/10.1111/fcp.12044
Blacher, Jacques, et al. "Management of hypertension in adults: the 2013 French Society of Hypertension guidelines." Fundamental & clinical pharmacology vol. 28,1 (2014): 1-9. doi: https://doi.org/10.1111/fcp.12044
Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol. 2014 Feb;28(1):1-9. doi: 10.1111/fcp.12044. Epub 2013 Aug 19. PMID: 23952903.
Copy Download .nbib Format: NLM
In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.

Fundamental & clinical pharmacology

Alaaeldin R, Mustafa M, Abuo-Rahma GEA, Fathy M.
PMID: 34268806
Fundam Clin Pharmacol. 2021 Jul 16; doi: 10.1111/fcp.12708. Epub 2021 Jul 16.

BACKGROUND/AIM: SARS-CoV-2 is one of the coronavirus families that emerged at the end of 2019. It infected the respiratory system and caused a pandemic worldwide. Fluoroquinolones (FQs) have been safely used as antibacterial agents for decades. The antiviral activity...

Cite
Alaaeldin R, Mustafa M, Abuo-Rahma GEA, et al. In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12708.
Alaaeldin, R., Mustafa, M., Abuo-Rahma, G. E. A., & Fathy, M. (2021). In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12708
Alaaeldin, Rania, et al. "In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12708
Alaaeldin R, Mustafa M, Abuo-Rahma GEA, Fathy M. In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease. Fundam Clin Pharmacol. 2021 Jul 16; doi: 10.1111/fcp.12708. Epub 2021 Jul 16. PMID: 34268806; PMCID: PMC8444764.
Copy Download .nbib Format: NLM
Xanthotoxin enhances the anticonvulsant potency of levetiracetam and valproate in the 6-Hz corneal stimulation model in mice.

Fundamental & clinical pharmacology

Zagaja M, Bryda J, Szewczyk A, Szala-Rycaj J, Łuszczki JJ, Walczak M, Kuś K, Andres-Mach M.
PMID: 34216038
Fundam Clin Pharmacol. 2022 Feb;36(1):133-142. doi: 10.1111/fcp.12713. Epub 2021 Aug 16.

Xanthotoxin (8-methoxypsoralen; XANT) is a furanocoumarin that has many biological properties, including antiepileptic activity. This study evaluated the effect of XANT on the ability of classical and novel antiepileptic drugs to prevent seizures evoked by the 6-Hz corneal stimulation-induced...

Cite
Zagaja M, Bryda J, Szewczyk A, et al. Xanthotoxin enhances the anticonvulsant potency of levetiracetam and valproate in the 6-Hz corneal stimulation model in mice. Fundam Clin Pharmacol. 2021;36(1):133-142doi: 10.1111/fcp.12713.
Zagaja, M., Bryda, J., Szewczyk, A., Szala-Rycaj, J., Łuszczki, J. J., Walczak, M., Kuś, K., & Andres-Mach, M. (2022). Xanthotoxin enhances the anticonvulsant potency of levetiracetam and valproate in the 6-Hz corneal stimulation model in mice. Fundamental & clinical pharmacology, 36(1), 133-142. https://doi.org/10.1111/fcp.12713
Zagaja, Mirosław, et al. "Xanthotoxin enhances the anticonvulsant potency of levetiracetam and valproate in the 6-Hz corneal stimulation model in mice." Fundamental & clinical pharmacology vol. 36,1 (2022): 133-142. doi: https://doi.org/10.1111/fcp.12713
Zagaja M, Bryda J, Szewczyk A, Szala-Rycaj J, Łuszczki JJ, Walczak M, Kuś K, Andres-Mach M. Xanthotoxin enhances the anticonvulsant potency of levetiracetam and valproate in the 6-Hz corneal stimulation model in mice. Fundam Clin Pharmacol. 2022 Feb;36(1):133-142. doi: 10.1111/fcp.12713. Epub 2021 Aug 16. PMID: 34216038.
Copy Download .nbib Format: NLM
Activation of spinal ephrin-B3/EphBs signaling induces hyperalgesia through a PLP-mediated mechanism.

Fundamental & clinical pharmacology

Zhang P, Qiao Z, Pan S, Yang P, Zha Z, Sun S, Xu Q, Liu X, Xu N, Liu Y.
PMID: 34904278
Fundam Clin Pharmacol. 2021 Dec 13; doi: 10.1111/fcp.12742. Epub 2021 Dec 13.

Ephrin B/EphB signaling pathway is involved in the regulation of pain caused by spinal cord injury. However, the role of ephrin-B3/EphBs signaling in regulation of nociceptive information is poorly understood. In the present study, formalin-induced inflammatory pain, mechanical allodynia...

Cite
Zhang P, Qiao Z, Pan S, et al. Activation of spinal ephrin-B3/EphBs signaling induces hyperalgesia through a PLP-mediated mechanism. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12742.
Zhang, P., Qiao, Z., Pan, S., Yang, P., Zha, Z., Sun, S., Xu, Q., Liu, X., Xu, N., & Liu, Y. (2021). Activation of spinal ephrin-B3/EphBs signaling induces hyperalgesia through a PLP-mediated mechanism. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12742
Zhang, Pei, et al. "Activation of spinal ephrin-B3/EphBs signaling induces hyperalgesia through a PLP-mediated mechanism." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12742
Zhang P, Qiao Z, Pan S, Yang P, Zha Z, Sun S, Xu Q, Liu X, Xu N, Liu Y. Activation of spinal ephrin-B3/EphBs signaling induces hyperalgesia through a PLP-mediated mechanism. Fundam Clin Pharmacol. 2021 Dec 13; doi: 10.1111/fcp.12742. Epub 2021 Dec 13. PMID: 34904278.
Copy Download .nbib Format: NLM
Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review.

Fundamental & clinical pharmacology

Abadi B, Shahsavani Y, Faramarzpour M, Rezaei N, Rahimi HR.
PMID: 34212424
Fundam Clin Pharmacol. 2021 Jul 01; doi: 10.1111/fcp.12712. Epub 2021 Jul 01.

Glioblastoma multiforme (GBM) is known as the deadliest form of brain tumor. In addition, its high treatment resistance, heterogeneity, and invasiveness make it one of the most challenging tumors. Depression is a common psychological disorder among patients with cancer,...

Cite
Abadi B, Shahsavani Y, Faramarzpour M, et al. Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12712.
Abadi, B., Shahsavani, Y., Faramarzpour, M., Rezaei, N., & Rahimi, H. R. (2021). Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12712
Abadi, Banafshe, et al. "Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12712
Abadi B, Shahsavani Y, Faramarzpour M, Rezaei N, Rahimi HR. Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review. Fundam Clin Pharmacol. 2021 Jul 01; doi: 10.1111/fcp.12712. Epub 2021 Jul 01. PMID: 34212424.
Copy Download .nbib Format: NLM
Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis.

Fundamental & clinical pharmacology

Kabel AM, Arab HH, Abd Elmaaboud MA.
PMID: 33609317
Fundam Clin Pharmacol. 2021 Dec;35(6):968-978. doi: 10.1111/fcp.12661. Epub 2021 Mar 24.

BACKGROUND: Nitric oxide was reported to play an essential role in various physiological and pathological processes in the body. Recent reports suggested that nitric oxide may affect the pathogenesis of cancer. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor which...

Cite
Kabel AM, Arab HH, Abd Elmaaboud MA. Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis. Fundam Clin Pharmacol. 2021;35(6):968-978doi: 10.1111/fcp.12661.
Kabel, A. M., Arab, H. H., & Abd Elmaaboud, M. A. (2021). Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis. Fundamental & clinical pharmacology, 35(6), 968-978. https://doi.org/10.1111/fcp.12661
Kabel, Ahmed M, et al. "Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis." Fundamental & clinical pharmacology vol. 35,6 (2021): 968-978. doi: https://doi.org/10.1111/fcp.12661
Kabel AM, Arab HH, Abd Elmaaboud MA. Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis. Fundam Clin Pharmacol. 2021 Dec;35(6):968-978. doi: 10.1111/fcp.12661. Epub 2021 Mar 24. PMID: 33609317.
Copy Download .nbib Format: NLM
Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?.

Fundamental & clinical pharmacology

Guion-Firmin J, Tessier S, Montastruc JL.
PMID: 34856006
Fundam Clin Pharmacol. 2021 Dec 02; doi: 10.1111/fcp.12741. Epub 2021 Dec 02.

Diarrhea is an adverse drug reaction (ADR) widely reported with olmesartan, an angiotensin II receptor blocker (ARB). Isolated case reports described this ADR with other ARBs. The present study was performed to investigate if, among the different ARBs, some...

Cite
Guion-Firmin J, Tessier S, Montastruc JL. Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12741.
Guion-Firmin, J., Tessier, S., & Montastruc, J. L. (2021). Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12741
Guion-Firmin, Julia, et al. "Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12741
Guion-Firmin J, Tessier S, Montastruc JL. Diarrhea and angiotensin II receptor blockers: Is there any difference between the different drugs?. Fundam Clin Pharmacol. 2021 Dec 02; doi: 10.1111/fcp.12741. Epub 2021 Dec 02. PMID: 34856006.
Copy Download .nbib Format: NLM
(-)-Epicatechin improves body composition of male rats descendant of obese mothers postnatally fed with a high-fat diet.

Fundamental & clinical pharmacology

De Los Santos S, Coral-Vázquez RM, Menjivar M, de Los Ángeles Granados-Silvestre M, De la Rosa S, Reyes-Castro LA, Méndez JP, Zambrano E, Canto P.
PMID: 34984750
Fundam Clin Pharmacol. 2022 Jan 04; doi: 10.1111/fcp.12749. Epub 2022 Jan 04.

BACKGROUND: A combination of maternal obesity and high-fat diet (HFD) in offspring postnatal life has deleterious effects, and (-)-epicatechin (Epi) treatment can reverse these adverse effects. Objective To investigate whether Epi administration can modify fat mass, muscle mass, and...

Cite
De Los Santos S, Coral-Vázquez RM, Menjivar M, et al. (-)-Epicatechin improves body composition of male rats descendant of obese mothers postnatally fed with a high-fat diet. Fundam Clin Pharmacol. 2022;doi: 10.1111/fcp.12749.
De Los Santos, S., Coral-Vázquez, R. M., Menjivar, M., de Los Ángeles Granados-Silvestre, M., De la Rosa, S., Reyes-Castro, L. A., Méndez, J. P., Zambrano, E., & Canto, P. (2022). (-)-Epicatechin improves body composition of male rats descendant of obese mothers postnatally fed with a high-fat diet. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12749
De Los Santos, Sergio, et al. "(-)-Epicatechin improves body composition of male rats descendant of obese mothers postnatally fed with a high-fat diet." Fundamental & clinical pharmacology vol. (2022). doi: https://doi.org/10.1111/fcp.12749
De Los Santos S, Coral-Vázquez RM, Menjivar M, de Los Ángeles Granados-Silvestre M, De la Rosa S, Reyes-Castro LA, Méndez JP, Zambrano E, Canto P. (-)-Epicatechin improves body composition of male rats descendant of obese mothers postnatally fed with a high-fat diet. Fundam Clin Pharmacol. 2022 Jan 04; doi: 10.1111/fcp.12749. Epub 2022 Jan 04. PMID: 34984750.
Copy Download .nbib Format: NLM
Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program.

Fundamental & clinical pharmacology

Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger É, Mezaache S, Micallef J.
PMID: 34837277
Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27.

Accumulating evidence shows that some antidepressants are abused for their psychostimulant effects, but the extent of antidepressants abuse is unknown in subjects with opioid use disorders (OUD). The objective of this work is to assess the prevalence of antidepressant...

Cite
Dumonceau RG, Soeiro T, Lacroix C, et al. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12738.
Dumonceau, R. G., Soeiro, T., Lacroix, C., Giocanti, A., Frauger, �. �., Mezaache, S., & Micallef, J. (2021). Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12738
Dumonceau, Robinson Gravier, et al. "Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12738
Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger É, Mezaache S, Micallef J. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27. PMID: 34837277.
Copy Download .nbib Format: NLM
Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study.

Fundamental & clinical pharmacology

Guion-Firmin J, Tessier S, Lepelley M, Faillie JL, Montastruc JL.
PMID: 34260768
Fundam Clin Pharmacol. 2021 Jul 14; doi: 10.1111/fcp.12717. Epub 2021 Jul 14.

Diarrhoea is an adverse drug reaction of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril + valsartan. It was also described with olmesartan and more recently with other angiotensin receptor blockers. The study was performed to compare diarrhoea reports in...

Cite
Guion-Firmin J, Tessier S, Lepelley M, et al. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12717.
Guion-Firmin, J., Tessier, S., Lepelley, M., Faillie, J. L., & Montastruc, J. L. (2021). Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12717
Guion-Firmin, Julia, et al. "Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12717
Guion-Firmin J, Tessier S, Lepelley M, Faillie JL, Montastruc JL. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Fundam Clin Pharmacol. 2021 Jul 14; doi: 10.1111/fcp.12717. Epub 2021 Jul 14. PMID: 34260768.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 188 entries